Provided by Tiger Trade Technology Pte. Ltd.

MABPHARM-B

0.490
+0.0408.89%
Volume:2K
Turnover:990
Market Cap:2.02B
PE:49
High:0.495
Open:0.495
Low:0.495
Close:0.450
52wk High:0.810
52wk Low:0.310
Shares:4.12B
HK Float Shares:4.12B
Volume Ratio:0.13
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.010
ROE:58.49%
ROA:2.00%
PB:8.91
PE(LYR):49.00
PS:2.24

Loading ...

Mabpharm Reports 982% Surge in H1 2026 Net Profit as Core Products Drive 45% Revenue Growth

Bulletin Express
·
Sep 21

MABPHARM-B Reports No Change in Share Capital for August 2026; Public Float Remains Compliant

Bulletin Express
·
Sep 03

Mabpharm FY26 H1 Profit More than Doubled to RMB 31.36 Million; Revenue Rises 45.1% to RMB 397.94 Million

Reuters
·
Aug 28

MABPHARM-B Posts Stable Share Capital in July 2026; Confirms Compliance with 25% Public Float

Bulletin Express
·
Aug 04

Mabpharm-B Adopts Third Amended & Restated Memorandum and Articles, Sets New Governance Framework

Bulletin Express
·
Jun 26

Mabpharm gains NMPA clearance for CMAB807X denosumab injection, paving way for broader oncology-related revenue

Bulletin Express
·
Jun 24

Mabpharm-B Receives Approval for CMAB807X Leshu® (Denosumab Injection) Marketing Application

Stock News
·
Jun 24

Mabpharm Says NMPA Approves Cmab807x (denosumab Injection) NDA

Reuters
·
Jun 24

Mabpharm - Nmpa Approves Cmab807x (denosumab Injection) Nda

THOMSON REUTERS
·
Jun 24

BRIEF-Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA

Reuters
·
Jun 09

Mabpharm's Application for Osteoporosis Drug Approved in China

MT Newswires Live
·
Jun 09

Mabpharm secures NMPA approval for CMAB807 denosumab injection, marking its fourth commercialised biologic

Bulletin Express
·
Jun 09

Mabpharm-B Receives NMPA Approval for CMAB807, Its Denosumab Biosimilar

Stock News
·
Jun 09

Mabpharm says China NMPA approves denosumab injection CMAB807 for osteoporosis

Reuters
·
Jun 09

Mabpharm - Nmpa Approves Cmab807 (Denosumab Injection) Nda

THOMSON REUTERS
·
Jun 09

Mabpharm: No Share Capital Movements Recorded in May 2026 Monthly Return

Bulletin Express
·
Jun 02

Mabpharm-B Maintains 4.12 Billion Issued Shares in April 2026; 72.67 Million Options Remain Outstanding

Bulletin Express
·
May 06

MABPHARM-B 2025财年营收大涨并实现扭亏为盈,聚焦核心抗体研发与全球拓展

Bulletin Express
·
Apr 27

Mabpharm announces annual general meeting

Reuters
·
Apr 27

Mabpharm Schedules 26 June 2026 AGM to Approve 2025 Results, Board Re-elections, Dual Share Mandates and New Articles

Bulletin Express
·
Apr 27